Movement Alert|Ultragenyx Pharmaceutical Intraday Rise 5.03% in Regular Trading, London investor meeting and UK review progress support sentiment

Market Focus
11/19

On November 19, Ultragenyx Pharmaceutical rose 5.03% in Regular Trading, trading at $17.56 with turnover of $38.32 million.

The move aligned with recent company updates indicating it will participate in a London investor meeting, while the UK MHRA has accepted the marketing application for UX111 for Sanfilippo syndrome type A, helping improve near-term market sentiment.

Background context shows UX111 has entered the UK regulatory review process, a meaningful milestone for one of Ultragenyx Pharmaceutical’s rare-disease gene therapy candidates. Earlier analyst actions also reflected a constructive longer-term view: RBC Capital raised its price target to $40 from $35 while maintaining Outperform, and Wedbush lifted its target to $30 from $26 while keeping a Neutral rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10